Berenberg upgrades Novo Nordisk stock rating to Buy on growth outlook

Berenberg upgraded Novo Nordisk (NVO) from Hold to Buy, setting a new price target of DKK425.00, which suggests approximately 20% upside potential. This upgrade reflects a significant reset in market expectations following multiple guidance downgrades, enabling a more constructive outlook on the company's growth and valuation. Berenberg now favors Novo Nordisk over Eli Lilly in the obesity treatment sector, anticipating opportunities for the new CEO to drive upside surprises despite remaining hurdles.

Analysis

Berenberg has upgraded Novo Nordisk (NVO) to Buy from Hold, signaling a tactical shift in sentiment in the obesity treatment sector. The upgrade is notable as it occurs alongside a price target reduction to DKK425.00 from DKK610.00, suggesting the new Buy rating is predicated on a valuation reset rather than an improved fundamental outlook. The thesis is that multiple guidance downgrades since mid-2024 have sufficiently de-risked the stock, creating a lower bar for performance and allowing for a more constructive view on its growth prospects. This is reinforced by Berenberg's explicit switch in preference from competitor Eli Lilly (LLY) to NVO, stating that "Novo is no longer the elephant in the room." The investment bank identifies the company's new CEO as a potential catalyst who could deliver upside surprises, even while acknowledging that hurdles remain. The new DKK425.00 price target implies approximately 20% upside potential from current levels.

Key Decisions for Investors

• Investors should consider the upgrade on Novo Nordisk as a potential contrarian opportunity, as the bullish thesis is built on the stock's recent underperformance and reset market expectations rather than new positive catalysts.
• The explicit preference shift from Eli Lilly to Novo Nordisk suggests evaluating a pair trade, potentially going long NVO while reducing exposure to LLY to capitalize on the perceived relative valuation gap.
• Monitor announcements from Novo Nordisk's new leadership and upcoming earnings for evidence of the 'upside surprise' potential that underpins Berenberg's thesis, as the reduced price target indicates that risks are still present.